Abstract 84 Table 1
| Endpoints | ATG induction (n=162) | No ATG induction (n=55) | P-value |
|---|---|---|---|
| 1 Year Survival | 92.0% | 85.5% | 0.200 |
| 1 Year Freedom from DSA Development | 86.4% | 74.5% | 0.038 |
| 1 Year Freedom from Any-Treated Rejection | 84.0% | 78.2% | 0.425 |
| 1 Year Freedom from Acute Cellular Rejection | 96.3% | 94.5% | 0.599 |
| 1 Year Freedom from Antibody-Mediated Rejection | 88.9% | 92.7% | 0.379 |
| Endpoints | Pre-transplant DSA + ATG induction (n=13) | No pre-transplant DSA + ATG induction (n=149) | P-value |
| 1 Year Survival | 100% | 91.3% | 0.265 |
| 1 Year Freedom from de novo DSA Development | 61.5% | 57.7% | 0.798 |
| 1 Year Freedom from Any-Treated Rejection | 76.9% | 84.6% | 0.665 |
| 1 Year Freedom from Acute Cellular Rejection | 92.3% | 96.0% | 0.608 |
| 1 Year Freedom from Antibody-Mediated Rejection | 84.6% | 89.3% | 0.769 |